Commit Biologics closed a US$60 million (€54 million) Seed financing round. The company develops complement-powered immune engagers for cancer and autoimmune disease. Ackermans & van Haaren led the round, with AbbVie Ventures, M Ventures, Bioqube Ventures, Korys, and Novo Holdings participating.
Funding plans
The proceeds will fund IND-enabling work and an IND filing for COM002. COM002 was announced last week as the company's first development candidate. The financing will also advance a second program into IND-enabling development and expand the BiCE pipeline.
Company context
Commit was founded as a spin-out from Aarhus University. It is based in Copenhagen and Aarhus. The company focuses on developing immunotherapies for autoimmune disease, oncology, and beyond.
BiCE platform
BiCE antibodies turn IgG antibodies into complement-powered immune engagers. They recruit the complement protein C1q to remove diseased cells. The approach works without T cells and retains standard antibody properties.
New board members include Michael Rosenzweig, Charlotte Kremers, and Lenny Van Steenhuyse. They join following the final close. Commit plans to move COM002 toward the clinic with the new funding.